1) The indications for anticoagulation prior to cardioversion.
Introduction
The optimal management of a patient with new-onset atrial fibrillation (AF) is highly individualized. Frequently, the key management decision is whether or not to perform acute cardioversion. This decision involves asking two questions: (1) should cardioversion be performed at all? And, if so, (2) should cardioversion be performed acutely or should it be delayed?
To answer the first question, the benefits of sinus rhythm, the risks of cardioversion, and the likelihood of recurrence must be considered. The answer to the second question depends largely on the duration of AF. In patients who have had AF for < 48 hours, there is little reason to delay cardioversion unless there is a reversible trigger that may result in an early recurrence, or unless there is a high likelihood of spontaneous conversion. In patients who have had AF for > 48 hours, or in whom the duration is unclear, an atrial thrombus must be excluded by a transesophageal echocardiogram (TEE) if acute cardioversion is being considered, unless the situa-tion is emergent. An alternative approach is to delay cardioversion until the patient has been anticoagulated for 3 weeks. This avoids the need for a TEE and avoids hospitalization to initiate heparin, but prolongs the duration of symptoms and may diminish the probability of restoring sinus rhythm by allowing time for more atrial remodeling to occur. Indeed, the various strategies for managing an episode of AF are each associated with their own advantages and disadvantages. In this monograph, the issues surrounding the most appropriate management of an episode of AF will be reviewed.
Should Cardioversion be Performed?

Initial Evaluation
The initial evaluation of a patient with AF includes confirmation of the rhythm diagnosis, exclusion of Wolff-Parkinson-White syndrome, determination of symptom severity, evaluation for underlying heart disease, and identification of the cause. The accurate diagnosis of AF is important but is not always achieved. A recent survey of cardiologists and cardiology fellows found that 74% misdiagnosed an ECG of AF with prominent atrial activity (> 0.2 mV) in more than one lead, as atrial fiutter (unpublished data). A study of internal medicine house officers found that 31% of those surveyed misdiagnosed rapid AF as paroxysmal supraventricular tachycardia.' The same study found that 32% of the arrbytbmias treated witb adenosine at a university medical center were AFs. Altbougb tbe irregularity of tbe ventricular response may be less apparent wben tbe ventricular response is rapid, tbe ballmarks of AF can usually be identified.
Tbe Wolff-Parkinson-Wbite syndrome must be diagnosed early so tbat tbe use of AV nodal blocking agents, wbicb migbt accelerate accessory patbway conduction, can be avoided.^ Furtbermore, early diagnosis is important because successful ablation of tbe accessory patbway may prevent recurrent episodes of AF.^"* Patients witb AF associated witb severe symptoms, sucb as significant angina or bemodynamic instability, sbould undergo immediate electrical cardioversion. Tbis is in accordance witb Advanced Cardiac Life Support guidelines.^ For patients witb moderate symptoms, ventricular rate control can significantly improve symptoms and allow time to stabilize tbe patient wbile cardioversion is being considered.
Identification of cardiac patbology sucb as pericarditis, acute myocardial infarction, mitral stenosis, or bypertropbic cardiomyopatby will bave an impact on botb acute and long-term management of a patient witb AF. Tberefore, a careful bistory must be taken and a pbysical examination witb focused cardiac testing, wbicb sbould include a transtboracic ecbocardiogram, sbould be performed in patients wbo present witb AF. Tbe initial evaluation sbould also include identification of major reversible triggers before proceeding witb cardioversion. Attempts sbould be made to reverse triggers, sucb as severe bypoxemia, tbat migbt lead to an early recurrence of AF. For example, a patient witb severe respiratory distress may need ventilatory support and correction of bypoxemia before cardioversion is attempted.
Benefits of Sinus Rhythm
Tbere are many tbeoretical advantages to sinus rbytbm. Tbe most obvious benefit of sinus rbytbm is tbe bemodynamic advantage tbat occurs witb restoration of atrial mecbanical function and AV syncbrony. Altbougb it is difficult to predict wbicb patients are likely to feel better after cardioversion, patients witb diastolic dysfunction, commonly seen in tbe elderly and tbose witb bypertension, are dependent upon atrial contraction. It is commonly believed tbat patients witb congestive beart failure are more likely to benefit from a return of atrial function. However, patients witb advanced beart failure develop a restrictive ventricular filling pattern sucb tbat tbe atrial contribution to filling is minimal.^ Restoration of sinus rbytbm may not improve cardiac output. Tbis concept is supported by a study'' tbat found no improvement after 6 weeks in exercise peak VO2, cardiac dimensions, or neurobumoral status among patients witb mild to moderate beart failure wbo underwent cardioversion for AF.
A second benefit of cardioversion is control of tbe ventricular rate. Tbere is a significant risk of tacbycardia-induced cardiomyopatby among patients witb AF wbose ventricular response cannot be controlled.* In fact, some patients tbougbt to bave idiopatbic dilated cardiomyopatby and AF may bave first developed rapid AF tbat subsequently led to a cardiomyopatby.^ Any metbod to decrease tbe rate can improve ventricular function, including drugs, cardioversion,"' AV junction ablation," or modification.'^ Tberefore, patients witb refractory rapid ventricular rates sbould be strongly considered for cardioversion, regardless of tbe presence or absence of symptoms.
A tbird benefit of cardioversion is regularization of tbe ventricular rbytbm. Even wben tbe ventricular rate is well controlled, cardiac output is lower wben tbe ventricular rbytbm is irregular tban wben it is regular.'^ Tbis may explain wby patients witb congestive beart failure may be more likely to benefit from AV junction ablation and pacing compared witb AV node modification, despite tbe adverse bemodynamics caused by rigbt ventricular apical pacing."* A fourtb benefit is tbe potential for reducing tbe risk of tbromboembolic complications. Tbere are no data tbat demonstrate a reduction in stroke risk following maintenance of sinus rbytbm, but it appears tbat tbe development of left atrial tbrombi is associated witb left atrial enlargement and reduced atrial mecbanical function. Studies bave demonstrated an eventual improvement in left atrial mecbanical function following cardioversion'^ and bave indicated tbat tbe maintenance of sinus rbytbm may prevent atrial enlargement. "^ Tberefore, it is plausible tbat in patients witb risk factors for stroke during AF, restoration of sinus rbytbm reduces tbe risk of stroke over tbe long term. On tbe otber band, tbe causes of stroke in patients witb AF are multifactorial, and some factors, sucb as complex aortic plaques, may be responsible for an ongoing risk of stroke despite the restoration of sinus rhythm.
starting therapy with an additional drug to maintain sinus rhythm.
Likelihood of Successful Conversion and Recurrence
The likelihood of successful conversion and the likelihood of recurrent AF should be considered before an attempt at cardioversion. Most patients can be successfully converted to sinus rhythm. The primary predictors of failure to convert with external cardioversion are body mass and the duration of AF. A study of 80 patients who underwent external cardioversion found that gender, left atrial enlargement, electrode pad position, etiology of AF, presence of left ventricular failure, and prior treatment with verapamil or beta blockers did not predict cardioversion success.'"' For patients who fail pharmacologic and external cardioversion, internal cardioversion is an option."^ Therefore, patients should not be considered ineligible for cardioversion merely because the likelihood of initial failure is perceived to be high. The use of certain terminology in reference to AF such as "chronic" in the medical literature and in patients' records has compounded the problem of patients not being given the option of cardioversions. Patients who carry a diagnosis of "chronic" AF may have a long history of self-terminating episodes of AF (paroxysmal) or have non-self-terminating AF, and have either failed cardioversion (permanent AF) or have never had an attempt at cardioversion (persistent AF).'Â lthough many factors have been associated with recurrence of AF following successful cardioversion, such as left atrial size, presence of heart disease, age, and duration of AF,^^ the predictive value of each factor is not strong in every study. For example, left atrial size and duration of AF may not predict recurrence after cardioversion among patients treated with antiarrhythmic drugs.2' Therefore, at least one attempt at cardioversion often is appropriate before deciding that a patient should be left in AF. In some cases, however, even one attempt at cardioversion may not be worthwhile. For example, a 75-year-old man with a mechanical aortic valve who is found to be in AF with a controlled ventricular response, who has no symptoms attributable to the AF, and who has tolerated warfarin for several years may prefer to remain in AF instead of undergoing cardioversion and/or Should Cardioversion be Performed Acutely or Postponed?
Once it has been decided to perform cardioversion, it must be decided whether cardioversion should be performed acutely or should be delayed. This decision is based on many factors, but hinges upon the duration of AF.
The decrease in left atrial transport and stasis of blood that occurs with AF results in intravascular thrombogenesis, platelet activation, and thromboembolism.22-24 in addition, the immediate postcardioversion period is associated with left atrial mechanical dysfunction that persists for a time proportional to the duration of AF,' -*â ppears to be calcium mediated,2'' and further increases the risk of stroke. It is unclear how much time following the onset of AF must elapse before cardioversion might result in thromboembolism. A time of 48 hours is frequently used as a cutoff point, 25 because it has been shown that cardioversion in patients with AF for < 48 hours can be performed relatively safely without anticoagulation. One study^"' followed 375 patients who presented with AF thought to be of < 48 hours in duration and who either spontaneously converted or underwent cardioversion without heparin or warfarin. One patient had a stroke, one patient had a transient ischemic attack, and one patient had a peripheral embolism, indicating an overall thromboembolic risk of < 1%. However, some physicians advocate anticoagulation prior to cardioversion for all patients, regardless of the duration of AF, because clot formation may occur sooner than 48 hours and because estimates of the duration of a particular episode of AF may be inaccurate.
There is often uncertainty regarding the time of onset of an episode of AF. Patients with paroxysmal AF have been shown to have more sustained asymptomatic episodes than symptomatic episodes.2^^ Therefore, it is possible that some patients who present with AF have been fibrillating for several days before the onset of symptoms.
Because some patients with AF present with insidious symptoms of weakness or dyspnea, it is usually recommended that only patients who have had AF of < 48 hours in duration and who can pinpoint the time of onset with confidence should undergo cardioversion without anticoag-ulation. The remaining patients should undergo cardioversion only after measures have been taken to reduce the risk of stroke.
AF < 48 Hours in Duration
Acute cardioversion leads to prompt resolution of symptoms, avoids the need for anticoagulation, and prevents further electrical and mechanical remodeling in the atria. Therefore, there is little reason to delay cardioversion in patients who present with AF < 48 hours in duration. However, there are two situations in which a delay may be advantageous.
The first situation is when there is a high likelihood of spontaneous conversion. On average, the incidence of spontaneous cardioversion of new-onset AF is approximately 50%. A recent study of 356 patients with AF of < 72 hours in duration found an incidence of spontaneous conversion of 68%. 28 The only predictor of spontaneous conversion was presentation within 24 hours. Therefore, an example of a patient who may benefit from a delay in cardioversion is a young, otherwise healthy individual who develops AF after excessive alcohol consumption and who presents to the hospital within a few hours after the onset of symptoms. Another example is a patient who develops AF during a procedure such as cardiac catheterization or a dobutamine stress echocardiogram.
On the other hand, a patient in whom there is a contraindication to anticoagulation should undergo prompt cardioversion, despite a high likelihood of spontaneous conversion. For example, a patient who presents with gastrointestinal bleeding and AF of < 48 hours in duration should be cardioverted promptly, because if spontaneous conversion does not occur within 48 hours, the window of opportunity for a low likelihood of stroke will have been lost.
The second situation in which cardioversion should be postponed is when there is a persistent reversible trigger, which will probably result in an early recurrence if left uncorrected. An example is a patient with AF in the setting of thyrotoxicosis, in whom cardioversion should be deferred until the thyroid disease has been treated.
AF > 48 Hours in Duration
Patients with AF > 48 hours in duration should undergo steps to reduce the risk of embolism with cardioversion, regardless of the absence of traditional risk factors that have been associated with stroke during chronic AF. There are two general approaches to reduce the risk of thromboembolism. The first approach is anticoagulation with warfarin for 3 weeks prior to cardioversion. An alternative strategy is to perform a TEE and perform cardioversion after intravenous heparin is started if no thrombus is found.29 Anticoagulation for at least 4 weeks after conversion to sinus rhythm must be administered regardless of which approach is chosen. Both approaches are acceptable and are recommended by recently published ACC/AHA guidelines.3o The decision of which approach to follow depends on several factors.
There are advantages and disadvantages of early cardioversion using a TEE-guided approach for patients with AF > 48 hours in duration. One advantage is that symptomatic patients will benefit from the prompt resolution of symptoms. Another advantage is the avoidance of the risk and inconvenience associated with anticoagulation for 3 weeks prior to cardioversion. Although the bleeding risk during this 3-week period may be low, the precardioversion period of anticoagulation is often > 3 weeks because of the time required to achieve therapeutic anticoagulation with warfarin in some patients. Therefore, early cardioversion may avoid several weeks of delay.
A theoretical advantage of early cardioversion is a lower incidence of recurrence. It has been shown that an episode of AF results in shortening of atrial refractoriness (electrical remodeling) that promotes a recurrent episode of AF,^'-'^ arid repeated cardioversions may be associated with progressively longer arrhythmia-free intervals. Therefore, early cardioversion allows less time for electrical remodeling to occur and may be more likely to be followed by sustained sinus rhythm.
A disadvantage of the TEE-guided approach is the need for the patient to undergo a TEE. However, this is a safe procedure and often provides other valuable information. Therefore, for patients who are already in the hospital, there is little disadvantage to early cardioversion. The TEE-guided approach has been shown to be costeffective for inpatients.33 However, the early approach to cardioversion requires hospitalization to initiate heparin while starting warfarin. Therefore, a patient with AF who is minimally symptomatic and who has likely been in AF chronically would obtain little benefit from early cardioversion. An approach using a TEE-guided cardioversion followed by outpatient subcutaneous low-molecular weight heparin offers the advantages of early cardioversion and the benefit of avoiding hospitalization. This strategy awaits further study.
The other disadvantage of the TEE-guided approach is the dilemma created when a patient is found to have an atrial thrombus. It is clear that patients with a thrombus who have not been anticoagulated should not undergo cardioversion acutely, if possible. However, it is not clear when, if ever, cardioversion can be safely performed. It is possible that cardioversion could be safely performed following 3 weeks of anticoagulation, even if the atrial thrombus is still present. However, some investigators recommend a repeat TEE and more aggressive anticoagulation prior to cardioversion if a clot is still present. Aggressive steps to minimize an embolic stroke must be weighed against the risks of delaying cardioversion, the risks of hemorrhagic complications, and how likely the patient is to benefit from sinus rhythm.
AF Following Cardiac Surgery
Postoperative AF deserves special mention. AE is a common problem after open heart surgery and has unique features. AF occurs in patients who are in the hospital and monitored, is secondary to triggers that often resolve over time, may occur in patients who have a contraindication to anticoagulation, and often prolongs the hospital length of stay. AF following noncardiac surgery is less common, with an incidence of approximately 6%, but shares many of these features. 3"* Although there are effective prophylactic regimens for postoperative AF, such as beta blockers,35 sotalol,3<' and orally administered amiodarone,3^ AF continues to be a significant problem. Much of the pathology contributing to the initiation and perpetuation of AF following cardiac surgery, such as pericarditis and elevated catecholamines, resolves spontaneously over time. Therefore, a successful cardioversion may be followed by an early recurrence, and a delay in cardioversion may be followed by spontaneous conversion. In a study using temporary epicardial wires placed at the time of cardiac surgery for atrial defibrillation, the incidence of early recurrence (< 60 sec after defibrillation) following successful conversion of postoperative AF was
The decision of whether to perform cardioversion acutely depends on the anticipated length of stay and often is governed by logistical factors. For example, if a patient develops AF on the day of anticipated discharge and ventricular rate control is achieved within a short period of time, it may be preferable to initiate therapy with warfarin, continue drugs to control the rate, and discharge the patient when the cardioversion process is expected to prolong the hospital stay. In a recent study,^^ 12 patients with postoperative AF who were discharged from the hospital with warfarin and drugs for rate control but without any attempts at cardioversion were compared with 67 patients discharged after cardioversion. Patients discharged in AF had a shorter length of stay and lower hospital costs compared with patients discharged in sinus rhythm. However, if the resources to promptly perform cardioversion are available, the patient can be discharged on the same day and avoid the need for anticoagulation.
Cardioversion Technique and Risks
Cardioversion of AF can be achieved either pharmacologically or electrically. Pharmacologic cardioversion is associated with proarrhythmia, including sustained polymorphic ventricular tachycardia with drugs that prolong repolarization such as sotalol, incessant monomorphic ventricular tachycardia as seen with flecainide, and bradycardia. It remains controversial which outpatients should be hospitalized prior to initiation of oral antiarrhythmic therapy. It is likely that patients without structural heart disease can be safely treated as outpatients. However, a recent retrospective study found clinically significant complications during in-hospital monitoring in 1 of 5 patients started on sotalol, and absence of heart disease failed to distinguish a low-risk group.'*" Although not approved for use in the United States for AF, amiodarone appears to be safe when started in low doses and can be started on an outpatient basis even in the presence of heart disease.
For patients who are already hospitalized and monitored, intravenous options include procainamide, ibutilide, and amiodarone. Digoxin has no role in the conversion of AF. The Digitalis in Acute AF (DAAF) Trial included 239 patients and found that 51% of patients who received digoxin converted to sinus rhythm after 16 hours. compared with 46% of patients who received placebo.'" Ibutilide has recently been compared with procainamide and was found to have a higher cardioversion success rate than procainamide (51% vs 21%, P = 0.005).'*? The risk of sustained polymorphic ventricular tachycardia is approximately 2%, and appears to occur more commonly in women and in patients with congestive heart failure. An additional advantage of ibutilide is that when conversion is not initially achieved, the energy required to cardiovert may be lowered by ibutilide (unpublished data). Although initial trials suggested that amiodarone was effective in cardioversion, a randomized placebo-controlled trial of 100 patients found no benefit.'*Ê lectrical cardioversion is safe and highly effective.'*'* No antiarrhythmic drug therapy has a higher success rate. Electrical cardioversion was initially shown to be associated with more significant atrial "stunning" compared with pharmacologic cardioversion in nonrandomized trials.'*T herefore, it was felt that pharmacologic cardioversion might be associated with a lower risk of embolism. However, more recent studies'**" have found no difference in the effect on atrial function between electric and pharmacologic cardioversion. Complications associated with electrical cardioversion, including ventricular fibrillation and postconversion bradycardia, are rare. In fact, in a prospective study of 1,152 patients who underwent either pharmacologic or electrical cardioversion, only five patients died, all of whom were related to quinidine therapy for pharmacologic cardioversion.'*' Therefore, if the facilities are readily available, there is little reason to delay electrical cardioversion while treatment with antiarrhythmic drugs is instituted.
When there is a high likelihood of recurrence, it may be of value to have therapeutic plasma drug levels present at the time of cardioversion to avoid an early recurrence of AF. Therefore, in this case, it may be useful to delay electrical cardioversion. On the other hand, prophylactic drug therapy can usually be initiated after cardioversion, and in some patients can be avoided altogether. For example, it would be acceptable to use no antiarrhythmic drugs following cardioversion of a patient who presents with his or her first episode of AF.
Given the inefficiency of transthoracic energy delivery, high energies are required for successful external cardioversion. Therefore, sedation is required when the procedure is performed electively. Several anesthetics have been shown to be useful in this setting, including intravenous midazolam, propofol, and etomidate.'**"5o Electrophysiologists who are experienced with conscious sedation can safely administer sedation for the delivery of painful shocks.^' However, because some agents such as propofol are associated with a high incidence of apnea,'*^' their use is often restricted by hospitals to anesthesiologists. Low-energy transvenous cardioversion using specially designed catheters is an option for patients who cannot receive sedation.52,53 xhis concept has recently been expanded to the postoperative setting. Liebold et al.^^ were able to successfully initially convert 80% of patients who developed AF after cardiac surgery with a mean energy of 5 J delivered through temporary epicardial wires that were placed intraoperatively. Only 30% of the patients required sedation.
Conclusion
There is increasing evidence to support acute cardioversion in patients with AF. Acute cardioversion results in prompt resolution of symptoms, reduces the time allowed for electrical remodeling to occur, reduces the duration of postcardioversion atrial mechanical dysfunction, and avoids the need for anticoagulation when performed within 48 hours of onset of AF. When acute cardioversion is being considered in a stable patient with AF > 48 hours, a TEE should be performed to exclude an atrial thrombus prior to cardioversion, and 4 weeks of warfarin therapy should be continued after cardioversion.
The management of AF must be individualized and must consider the duration of AF, the perceived benefit of sinus rhythm, the likelihood of a spontaneous conversion, the presence of ongoing triggers, the need for hospital admission, and logistical factors. Although clinical judgment will always play an important role in determining the optimal treatment strategy in individual patients, additional prospective studies are needed to clarify unsettled issues related to AF. For example, it is unclear whether acute cardioversion or rate control/anticoagulation is the safer and least costly strategy in patients with postoperative AF. In addition, the role of newer agents for anticoagulation such as subcutaneous low-molecular weight heparin, and the role of newer techniques that permit low-energy cardio-version without sedation remain to be determined.
